TrivarX Limited (ASX:TRI) has secured the stable isotope compound needed for its upcoming Phase 1 trial of the Stabl-IM imaging platform, which aims to non-invasively visualize actively replicating brain tumor cells without radioactive tracers or biopsies. The company, which pivoted from mental health diagnostics to focus on this oncology technology, plans to begin the trial with healthy volunteers by the end of 2026. This crucial supply milestone enhances the trial’s feasibility, allowing the company to advance toward clinical testing and regulatory submissions in the US and EU. Investors should monitor the trial’s commencement, safety data, and regulatory progress, while being aware of the associated financial and execution risks characteristic of early-stage medtech ventures.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://kalkine.com.au/news/healthcare/trivarx-asxtri-secures-critical-supply-for-its-stabl-im-imaging-clinical-trial
